Divalproex versus placebo for the prevention of irritability associated with fluoxetine treatment in autism spectrum disorder.
Anagnostou
Evdokia
E
Esposito
Katherine
K
Soorya
Latha
L
Chaplin
William
W
Wasserman
Stacey
S
Hollander
Eric
E
D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects / Q000627:therapeutic use; D018692:Antimanic Agents / Q000627:therapeutic use; D001321:Autistic Disorder / Q000188:drug therapy* / Q000523:psychology; D002648:Child; D004311:Double-Blind Method; D005473:Fluoxetine / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007508:Irritable Mood / Q000187:drug effects*; D010919:Placebos; D016896:Treatment Outcome; D014635:Valproic Acid / Q000627:therapeutic use*
D018687:Antidepressive Agents, Second-Generation; D018692:Antimanic Agents; D010919:Placebos; D005473:Fluoxetine; D014635:Valproic Acid